Malignant Melanoma Recurrence - How To Avoid It After Targeted Treatment
According to a study published in the New England Journal of Medicine, researchers at The Institute of Cancer Research (ICR) have demonstrated how to prevent new cancers that can occur when malignant melanoma patients are treated with drugs known as BRAF inhibitors. In the past, doctors have observed that between 15 and 30% of patients who were treated with BRAF inhibitors, including the FDA-approved drug vemurafenib ( Zelboraf ), developed another type of skin cancer known as cutaneous squamous cell carcinoma, which required surgical removal.
New Biomarkers Tested For Rapid Diagnosis Of Severe Kidney Damage
How does a doctor determine whether or not an emergency-room patient has acute kidney injury? Using tests currently available in the hospital, this question is often difficult to answer. In many emergency cases, however, early diagnosis of the severity of the disease picture is crucial. A large multicenter study by clinicians of the Experimental and Clinical Research Center (ECRC), a joint cooperation between the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch and the Charite - Universitatsmedizin Berlin, the Helios Hospital Berlin, and two hospitals in the U.
Fixing Common Blood Disorder Would Make Kidney Transplants More Successful
Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that aggressively treating anemia may help save the kidneys and possibly the lives of many transplant recipients. Anemia commonly arises in patients with kidney disease because the kidneys secrete most of the hormone erythropoietin that stimulates red blood cell production.